Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market

Description:

GBI Research, a leading business intelligence provider, has released its latest research report, “Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market”. The value of the Non-Small Cell Lung Cancer (NSCLC) market is expected to increase significantly over the forecast period across the leading eight developed nations, from $5.1 billion in 2013 to $7.9 billion in 2020. This equates to a Compound Annual Growth Rate (CAGR) of 6.6%. Growth will be driven by novel therapies entering the squamous cell carcinoma market segment, which is currently lacking effective treatment, unlike the non-squamous market segment. – PowerPoint PPT presentation

Number of Views:75

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market


1

Non-Small Cell Lung Cancer Market to 2020 - New
Therapies to Enhance Treatment Segmentation and
Drive Growth in an Increasingly Competitive Market

Published By GBI Research
Published May 2014
2
Description


GBI Research, a leading business intelligence
provider, has released its latest research
report, Non-Small Cell Lung Cancer Market to
2020 - New Therapies to Enhance Treatment
Segmentation and Drive Growth in an Increasingly
Competitive Market. The value of the Non-Small
Cell Lung Cancer (NSCLC) market is expected to
increase significantly over the forecast period
across the leading eight developed nations, from
5.1 billion in 2013 to 7.9 billion in 2020.
This equates to a Compound Annual Growth Rate
(CAGR) of 6.6. Growth will be driven by novel
therapies entering the squamous cell carcinoma
market segment, which is currently lacking
effective treatment, unlike the non-squamous
market segment. The report focuses on the
increasing differentiation between the three main
NSCLC subtypes squamous cell, adenocarcinoma,
and large cell carcinoma. Common genetic and
molecular aberrations within these histologies
are being extensively researched and targeted by
novel therapeutics and so the treatment algorithm
between histological subtypes is forecast to
become more differentiated over the forecast
period.
3
Description


Most notably, patients with squamous cell
carcinoma are set to benefit from crucial first-
and second-line therapies in the form of Yervoy
(ipilimumab) and nivolumab, having relied on
generic chemotherapy for the past decade.
Non-squamous patients, on the other hand, have
several successful histology-specific therapies,
such as Alimta (pemetrexed), and
mutation-specific therapies, such as Tarceva
(erlotinib), that are already marketed. New
second-line entrants will create a crowded and
competitive environment. The generic erosion of
market leaders Alimta and Tarceva late in the
forecast period will make this a tough
environment for new products that have shown only
minor improvements in safety or efficacy. Despite
the potential of targeted therapies and the
identification of several promising molecular
targets, the development of these products
remains in the early-stage pipeline. Epidermal
Growth Factor Receptor (EGFR) and Anaplastic
Lymphoma Kinase (ALK) mutations are likely to
remain the only identified intracellular
molecular aberrations targeted by marketed
products, both of which are mainly found in
adenocarcinoma tumors.
4
Description


Instead, the late-stage pipeline is primarily
occupied by immunotherapies, which still offer a
greater degree of specificity than
chemotherapies however, they initiate tumor
destruction via the immune system. Necitumumab,
Yervoy and nivolumab are all Phase III
immunotherapies expected to reach the market in
the forecast period, each with a different
target. Resistance to targeted therapies is a
significant issue in the NSCLC market as the
onset of acquired resistance to therapies such as
Tarceva or Xalkori (crizotinib) has greatly
reduced their potential. Despite the limited
late-stage pipeline activity with new molecular
targets, there are new drugs targeting EGFR and
ALK that may combat resistance, thereby
increasing the time frame in which patients are
treatable with targeted therapy. Gilotrif
(afatinib) is a recently launched EGFR inhibitor
with a novel mechanism of action that may delay
the onset of resistance, and Zykadia (LDK378) is
an ALK inhibitor in the late-stage pipeline that
is set to treat Xalkori-resistant patients.
5
Description

Scope The report analyzes treatment usage
patterns, market characterization, pipeline
analysis and key licensing and co-development
deals in critical care in the eight major
developed markets of the US, UK, France, Germany,
Italy, Spain, Japan and Canada. The report
includes - - A brief introduction to the five
major plasma-derived products in critical care
and the indications that they are being used to
treat, as well as disease overview, epidemiology,
other treatment options, and treatment patterns -
Analysis of major marketed products in critical
care, covering product performance in terms of
the safety and efficacy of recent approvals - A
review of the critical care pipeline, including
individual analysis of promising late-stage
pipeline drugs that are most likely to enter the
market during the forecast period
6
Description

Reasons to buy The report will enhance your
decision-making capability by allowing you to -
- Align your product portfolio to markets with
high growth potential - Develop market entry and
expansion strategies by identifying the regions
and therapeutic segments poised for strong
growth - Devise effective, tailored strategies
for each country through the understanding of key
drivers and barriers in the critical care drugs
market - Develop key strategic initiatives based
on an understanding of key focus areas and
leading companies - Accelerate and strengthen
your market position by identifying key companies
for mergers, acquisitions and strategic
partnerships
7
Table of Contents

  • 1 Table of Contents
  • 2 Introduction
  • 3 Marketed Products
  • 3.1 Overview
  • 3.2 Chemotherapies - Various
  • 3.3 Large Cell Carcinoma
  • 4 NSCLC Pipeline
  • 4.3 Clinical Trials
  • 5 Market Forecast
  • 5.1 Geographical Markets
  • 5.1.2 North America

8
Table of Contents

  • 6 Strategic Consolidations
  • 6.1 CancerVax Enters into an Agreement with
    CIMAB and YM Biosciences
  • 7 Appendix
  • For inquiry, kindly contact at
    http//www.reportsandintelligence.com/enquire-abou
    t-report/132454
  • To check table of contents of the research, Visit
    _at_ http//www.reportsandintelligence.com/non-small
    -cell-lung-cancer-to-2020-new-therapies-to-enhance
    -treatment-segmentation-and-drive-growth-in-an-inc
    reasingly-competitive-market/table-of-contents

9

FOR MORE DETAILS
Visit us at
http//www.reportsandintelligence.com/non-small-ce
ll-lung-cancer-to-2020-new-therapies-to-enhance-tr
eatment-segmentation-and-drive-growth-in-an-increa
singly-competitive-market
Stay With Us
TELEPHONE Direct 1 (617) 674-4143 Toll Free
1 (855) 711-1555 E-MAIL sales_at_reportsandintellig
ence.com
5933 NE Win Sivers Drive, 205, Portland, OR
97220 United States
About PowerShow.com